|Mr. Juan Ramón Alaix||Chief Exec. Officer and Director||3.17M||N/A||66|
|Mr. Glenn C. David||Chief Financial Officer and Exec. VP||1.08M||370.4k||N/A|
|Dr. Catherine A. Knupp||Exec. VP and Pres of R&D||1.09M||N/A||56|
|Mr. Clinton A. Lewis Jr.||Exec. VP and Pres of International Operations||2.17M||N/A||50|
|Ms. Kristin C. Peck||Exec. VP and Pres of US Operations||1.32M||N/A||46|
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the United States and internationally. It offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms. The company also provides medicated feed additives that offer medicines to livestock; and other pharmaceutical products, including pain and sedation, oncology, antiemetic, allergy and dermatology, and reproductive products. In addition, it offers other product categories comprising nutritionals and agribusiness services, as well as products and services in complementary areas consisting of biodevices, diagnostics, and genetics. The company markets its products to veterinarians and livestock producers through its sales representatives, and technical and veterinary operations specialists. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.
Zoetis Inc.’s ISS Governance QualityScore as of August 1, 2017 is 8. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 9; Compensation: 3.